{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:41:49Z","timestamp":1774374109285,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.maturitas.2014.06.011","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T14:46:04Z","timestamp":1403189164000},"page":"117-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Spanish Menopause Society position statement: Use of denosumab in postmenopausal women"],"prefix":"10.1016","volume":"79","author":[{"given":"Antonio","family":"Cano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Silvan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"Bar\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Villero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Quereda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00e1s","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"S\u00e1nchez-Borrego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2014.06.011_bib0005","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.maturitas.2013.05.021","article-title":"Spanish Menopause Society. 2013 Up-date of the consensus statement of the Spanish Menopause Society on postmenopausal osteoporosis","volume":"76","author":"Mendoza","year":"2013","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0010","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00198-013-2436-0","article-title":"Sequential use of antiresorptives in younger women","volume":"25","author":"Cano","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0015","unstructured":"http:\/\/cebgrade.mcmaster.ca\/."},{"key":"10.1016\/j.maturitas.2014.06.011_bib0020","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1210\/er.2007-0038","article-title":"Osteoimmunology: interactions of the bone and immune system","volume":"29","author":"Lorenzo","year":"2008","journal-title":"Endocr Rev"},{"issue":"5","key":"10.1016\/j.maturitas.2014.06.011_bib0025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cytogfr.2013.06.001","article-title":"Osteoprotegerin: multiple partners for multiple functions","volume":"24","author":"Baud\u2019huin","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"issue":"April","key":"10.1016\/j.maturitas.2014.06.011_bib0035","article-title":"Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM Study Extension","author":"Brown","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0040","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0045","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0050","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jc.2010-1805","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial","volume":"96","author":"Miller","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.maturitas.2014.06.011_bib0055","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00198-012-2052-4","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial","volume":"24","author":"McClung","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0060","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0065","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0070","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0075","first-page":"1953","volume":"25","author":"Brown","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0080","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0085","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0090","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","article-title":"The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension","volume":"98","author":"Bone","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0095","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/GME.0b013e318267f909","article-title":"Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.reuma.2012.06.007","article-title":"Denosumab for the treatment of osteoporosis: a systematic literature review","volume":"9","author":"Silva-Fern\u00e1ndez","year":"2013","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0105","unstructured":"http:\/\/www.proliahcp.com\/pdf\/dear_healthcare_professional_letter.pdf."},{"key":"10.1016\/j.maturitas.2014.06.011_bib0110","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00198-011-1755-2","article-title":"Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?","volume":"23","author":"Watts","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0115","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00198-009-1023-x","article-title":"Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass","volume":"21","author":"Kendler","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/GME.0b013e31828f5e5d","article-title":"Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study","volume":"21","author":"Kendler","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0125","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0130","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.maturitas.2013.04.016","article-title":"Position of the Spanish Menopause Society regarding the management of menopausal symptoms in breast cancer patients","volume":"75","author":"S\u00e1nchez-Borrego","year":"2013","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0135","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0140","unstructured":"http:\/\/clinicaltrials.gov\/show\/NCT00556374."},{"key":"10.1016\/j.maturitas.2014.06.011_bib0145","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/1078-0432.CCR-10-2507","article-title":"Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL\/RANK\/OPG pathway in tumorigenesis and metastasis","volume":"18","author":"Dougall","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0225","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0155","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0160","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0165","unstructured":"http:\/\/clinicaltrials.gov\/show\/NCT01077154."},{"key":"10.1016\/j.maturitas.2014.06.011_bib0170","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2165\/11589310-000000000-00000","article-title":"Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal","volume":"29","author":"Scotland","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"Suppl. 1","key":"10.1016\/j.maturitas.2014.06.011_bib0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3111\/13696998.2012.737393","article-title":"Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada","volume":"15","author":"Chau","year":"2012","journal-title":"J Med Econ"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0180","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00198-012-2115-6","article-title":"Intervention thresholds for denosumab in the UK using a FRAX\u00ae-based cost-effectiveness analysis","volume":"24","author":"Str\u00f6m","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0185","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2165\/11539980-000000000-00000","article-title":"Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium","volume":"29","author":"Hiligsmann","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0190","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1586\/erp.12.76","article-title":"Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women","volume":"13","author":"Hiligsmann","year":"2013","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0195","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40258-013-0047-8","article-title":"Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US","volume":"11","author":"Parthan","year":"2013","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0200","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bone.2013.11.002","article-title":"Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective","volume":"59","author":"Parthan","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0205","first-page":"621","article-title":"Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases","volume":"17","author":"Xie","year":"2011","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3111\/13696998.2012.719054","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis","volume":"16","author":"Snedecor","year":"2013","journal-title":"J Med Econ"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0215","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clbc.2012.04.001","article-title":"Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases","volume":"12","author":"Xie","year":"2012","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0220","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.clinthera.2012.04.008","article-title":"Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer","volume":"34","author":"Snedecor","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17290","article-title":"Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours","volume":"17","author":"Ford","year":"2013","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.maturitas.2014.06.011_bib0235","first-page":"1785","article-title":"Comparing cost-effectiveness analyse s of denosumab versus zoledronic acid for the treatment of bone metastases","volume":"21","author":"Koo","year":"2013","journal-title":"Support Care Cancer"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512214002072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512214002072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:00:18Z","timestamp":1759914018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512214002072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0378512214002072"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2014.06.011","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spanish Menopause Society position statement: Use of denosumab in postmenopausal women","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2014.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}